Patents by Inventor Volker Germaschewski

Volker Germaschewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11858996
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 2, 2024
    Assignee: KYMAB LIMITED
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
  • Publication number: 20230312720
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: September 1, 2022
    Publication date: October 5, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Ian KIRBY, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Publication number: 20230233675
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 27, 2023
    Applicant: Kymab Limited
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Martin YATEMAN, Jasper CLUBE, Steve ARKINSTALL
  • Publication number: 20230192859
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: June 22, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Publication number: 20230192847
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: July 15, 2022
    Publication date: June 22, 2023
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • Patent number: 11648308
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 16, 2023
    Assignee: Kymab Limited
    Inventors: Volker Germaschewski, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
  • Publication number: 20230025129
    Abstract: Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 26, 2023
    Inventors: Matthew WAKE, Volker GERMASCHEWSKI, Igor THEURL, Jonathan Leslie PAPWORTH, Delphine MEYNARD
  • Publication number: 20220403029
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 22, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • Publication number: 20220380467
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 1, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • Patent number: 11440960
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 13, 2022
    Assignee: KYMAB LIMITED
    Inventors: Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies
  • Publication number: 20220073598
    Abstract: The invention relates to Bone Morphogenetic Protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
    Type: Application
    Filed: August 15, 2019
    Publication date: March 10, 2022
    Inventors: Volker GERMASCHEWSKI, Igor THEURL, Joana de Abreu CARVALHO, Morgane Marie LECOINTRE, Jonathan Leslie PAPWORTH, Luke Thomas BAYLISS, Verena PETZER
  • Publication number: 20210380699
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 9, 2021
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • Publication number: 20210214456
    Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
    Type: Application
    Filed: June 11, 2019
    Publication date: July 15, 2021
    Inventors: Martina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI
  • Publication number: 20200267952
    Abstract: The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 27, 2020
    Inventors: Volker Germaschewski, E-Chiang Lee, Hanif Ali, Jasper Clube
  • Patent number: 10703814
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 7, 2020
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • Publication number: 20200190191
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 18, 2020
    Inventors: Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Patent number: 10667501
    Abstract: The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: June 2, 2020
    Assignee: Kymab Limited
    Inventors: Volker Germaschewski, E-Chiang Lee, Hanif Ali, Jasper Clube
  • Publication number: 20200131267
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 30, 2020
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Publication number: 20190338032
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: November 7, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, IAN KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stphen Douglas GILLIES